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Abstract
Background: The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed
to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage
treatment for in-field recurrence of high-grade gliomas.
Methods: Between January 2016 and October 2019, 70 patients with rHGG who underwent HSRS were
retrospectively analysed. The primary endpoint was overall survival (OS), and secondary endpoints included both
progression-free survival (PFS) and adverse events, which were assessed according to Common Toxicity Criteria
Adverse Events (CTCAE) version 5. The prognostic value of key clinical features (age, performance status, planning
target volume, dose, use of bevacizumab) was evaluated.
Results: A total of 70 patients were included in the study. Forty patients were male and 30 were female. Forty-nine
had an initial diagnosis of glioblastoma (GBM), and the rest (21) were confirmed to be WHO grade 3 gliomas. The
median planning target volume (PTV) was 16.68 cm3 (0.81–121.96 cm3). The median prescribed dose was 24 Gy
(12–30 Gy) in 4 fractions (2–6 fractions). The median baseline of Karnofsky Performance Status (KPS) was 70
(40–90). With a median follow-up of 12.1 months, the median overall survival after salvage treatment was 17.6
months (19.5 and 14.6 months for grade 3 and 4 gliomas, respectively; p = .039). No grade 3 or higher
toxicities was recorded. Multivariate analysis showed that concurrent bevacizumab with radiosurgery and
KPS > 70 were favourable prognostic factors for grade 4 patients with HGG.
Conclusions: Salvage HSRS showed a favourable outcome and acceptable toxicity for rHGG. A prospective
phase II study (NCT04197492) is ongoing to further investigate the value of hypofractionated stereotactic
radiosurgery (HSRS) in rHGG.
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Introduction
The most frequently diagnosed malignant primary brain
tumour in adults is high-grade glioma (HGG). In the
United States [1], there are 2.96 newly diagnosed oc-
currences per 100,000 people per year, while the num-
ber in China is up to 5 to 8. Despite definitive primary
therapy, including surgery, adjuvant chemoradiation
and temozolomide-based chemotherapy [2], nearly all
patients experience tumour recurrence [3], up to 90%
of which is local recurrence [4].
The clinical outcome of recurrent rHGG is poor, and
there is no consensus on the optimal treatments, which
consist of surgery, reirradiation systemic therapy and
tumour treating fields (TTFs). Surgery has been reported
to have a median OS of 9.7 months, whereas less than
30% of patients could undergo the operation due to the
involvement of eloquent areas and the infiltrative nature
of glioma [5–7]. Systemic therapy has a median OS ran-
ging from 6 to 9months [8–10]. The efficacy of salvage
systemic therapy is limited because of the cumulative tox-
icity and resistance of chemotherapy agents [11]. For TTF,
the median OS reported in EF-14 was 6.6months [12].
Radiotherapy is also known as an option for rHGG. Sev-
eral small sample prospective studies reported a promising
outcome and acceptable toxicity with a median OS of 12
to 12.7months after salvage treatment [13–16].
HSRS can deliver a high radiation dose while limiting
toxicity to normal tissues. CyberKnife is a radiosurgery
system that allows highly conformal image-guided radio-
therapy and shows a promising tumour control effect for
central nervous system tumours. This study aims to de-
termine the treatment outcome and toxicity of HSRS.
To our knowledge, this is the largest cohort of rHGGs
treated with HSRS as a first-line salvage treatment.
Methods
Eligibility criteria and endpoints
All participants provided written informed consent, and
studies were approved by the local ethics committee.
Between January 2016 and October 2019, patients with
recurrent HGG who received salvage HSRS using Cyber-
Knife at HuaShan Hospital were included. All patients
had initially histologically confirmed World Health
Organization (WHO) grade 3/4 glioma and received ad-
juvant external-beam radiation with concomitant temo-
zolomide and adjuvant temozolomide. HGG recurrence
was confirmed by RANO criteria and/or stereotactic
brain biopsy. All patients were treated at first recurrence
within the radiation field.
The primary endpoint was overall survival from the
completion of salvage HSRS (OS-HSRS). The second
endpoints included progression-free survival after sal-
vage treatment and toxicity defined by CTCAE 5.0.
Baseline evaluation and treatment delivery
HSRS was performed using the Radiosurgery System
(Accuray, Sunnyvale, CA, USA). Patients were immobi-
lized with a custom thermoplastic mask and underwent
both computed tomography (CT, GE Light speed Ultra
16 Slice, USA) examinations with a slice thickness of
1.25 mm and MRI with a slice thickness of 2 mm ac-
quired from both T1 postcontrast and T2 flair images.
CT and MRI scans were then fused using the planning
system for contouring.
Radiation oncologists, neurosurgeons, and radiation
physicists participated in tumour delineation, planning,
and dose selection. Gross tumour volume (GTV) was de-
fined as the gadolinium-enhanced tumour on the T1-
weighted series. The clinical tumour volume (CTV) was
considered equal to the GTV. The planning target vol-
ume (PTV) was a uniform 2mm expansion of the CTV,
and FLAIR abnormalities were not included in the treat-
ment volume. Multiplan (Accuray, Sunnyvale, CA, USA)
software was used for inverse planning. The prescribed
dose to PTV was determined according to the target vol-
ume, site, previous irradiation volume and total dose,
and the interval between treatments.
The use of systemic therapy after HSRS was decided
by the treating physicians. Thus, the regimens were indi-
vidualized, and most commonly, bevacizumab, temozo-
lomide or clinical trials were recommended.
Assessment and toxicity
All patients underwent clinical and radiological follow-
up every 3 m after HSRS. If any significant deterioration
in the patient’s performance occurred, an MRI was or-
dered immediately. The radiological examination in-
cluded MRI and other necessary examinations, such as
MRI-based spectroscopy, perfusion MRI, and methio-
nine positron emission tomography. KPS after treatment,
adverse event occurrence, and associated clinical out-
comes were recorded. Toxicity was assessed using the
CTCAE 5.0.
Statistics
The primary outcome was overall survival after HSRS,
defined as survival from the time of the completion of
HSRS to death due to any cause. Other measures in-
cluded progression-free survival after salvage treatment
and treatment-related toxicities.
Survival curves were estimated using the Kaplan-Meier
method and compared with the log-rank test.
Multivariate analysis of OS-HSRS in WHO grade 4 gli-
oma patients was performed using a Cox proportional
hazards regression model. Variables included in the
multivariate analysis model were those with hypotheses
of interest or determined to be clinically related to sur-
vival. Age, PTV, biologically effective dose (the median
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BED was 37.5 Gy, BED was calculated using the LQ
model with an alpha/beta ratio of 10, and KPS and con-
current bevacizumab regimen (defined as bevacizumab
administered during HSRS) were factors included in the
multivariate analysis. The multivariable Cox regression
model results are reported as hazard ratios with 95% CI
and p values. All statistical analyses were performed in R
version 3.6.1 using the survminer and survival packages.
Results
Patient characteristics
Between January 2016 and October 2019, 70 high-grade
glioma patients who had clinical, radiographic and/or
stereotactic brain biopsy evidence of recurrence were
treated with CyberKinfe (Fig. 1). All patients were ini-
tially treated with maximum safe resection and adjuvant
radiation treatment with a median dose of 60 Gy in 30
fractions with concurrent and maintenance temozolo-
mide. Forty patients were male and 30 were female. The
median age was 53 years (range 20–76 years). The ma-
jority of patients (49) had an initial diagnosis of glio-
blastoma, and the rest (21) had WHO grade 3 gliomas.
The median time from the initial diagnosis to salvage
HSRS was 13.7 months, with a range of 4.2 to 55.3
months.
The median volume of salvage HSRS PTV was 16.68
cm3 (0.81–121.96 cm3). The treatment was given daily,
and the median dose was 24 Gy (12–30 Gy) in 4 frac-
tions (2–6 fractions), with a median isodose line of 70%
(63–75%). Patient characteristics are listed in Table 1.
Compliance and toxicities
All patients completed planned HSRS without interrup-
tion. There was no significant treatment-related acute
toxicity (grade ≥ 3). Common nonhaematologic grade 2
toxicities included fatigue (9 cases, 12.9%), nausea/
vomiting (7 cases, 10.0%) and headache (4 cases, 5.7%).
Toxicity details are shown in Table 2.
Other toxicities included hypertension, seizure and
haematologic toxicities that were considered chemother-
apy related. No complications were related to acute or
late toxicity of HSRS.
Treatment outcomes
By the end of the study, 26 patients died of tumour pro-
gression. The median follow-up from the time of HSRS
Fig. 1 Flow diagram of this retrospective study
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was 12.1 months. The median overall survival after sal-
vage treatment was 17.6 months for the whole cohort
(Fig. 2a, 14.5 to 26.1 months, 95% CI) and 19.5 and 14.6
months for grade 3 and 4 gliomas, respectively (Fig. 2b,
p = 0.039). The overall survival rates following HSRS
were 72.8, 30.1, and 18.0% at 1, 2, and 3 years,
respectively.
All patients were assessed by the RANO criteria, and
42 patients had progressive disease. Twelve of the pa-
tients (28.6%) had new lesions outside the radiation field,
and 30 patients (71.4%) had local recurrence (LR). The
6-month PFS was 76.3 and 57.1% for grade 3 and 4 pa-
tients, respectively. The median PFS was 7.0 months (5.9
to 9.2 months, 95% CI) and 7.6 and 6.8 months for
grades 3 and 4, respectively (p = 0.077). Twenty-four pa-
tients received a second-course salvage treatment be-
cause of radiographic progression, and two of them
received surgery.
On multivariate analysis, KPS > 70 (HR = 0.13, p =
0.0060) and bevacizumab concurrently administered
with HSRS (defined as bevacizumab administered during
HSRS, HR = 0.15, p = 0.0040) were factors that positively
affected OS after salvage HSRS for grade 4 patients
(Table 3). The one-year OS rates after HSRS in grade 4
patients who had concurrent bevacizumab with HSRS
and those who did not were 77.3 and 56.0%, respectively
(Fig. 2c, p = 0.035). Grade 4 patients with a KPS > 70 be-
fore treatment also showed a longer OS than those with
a KPS ≤ 70 (Fig. 2d, p = 0.041).
There was no significant difference in age, sex, KPS,
mutation status, time from the initial diagnosis to HSRS
or PTV between these two groups.
Discussion
Salvage treatment options for recurrent high-grade
Glioma
For rHGG patients, salvage treatment included surgery,
reirradiation, systemic therapy, and TTF. Although the








Initial histological WHO grade
3 21 30
4 49 70
Interval between HSRS and initial diagnosis (months)
Median 13.7 /
Range 1.1–55.3 /





















TMZ + BVZ 7 10
BSC 21 30
Total 70 100
Abbreviations: WHO World Health Organization, HSRS hypofractionated
stereotactic radiosurgery, KPS Karnofsky performance status, MGMT O6-
methylguanine-DNA methyltransferase, IDH1 Isocitrate dehydrogenase 1, TMZ
Temozolomide, BVZ Bevacizumab, BSC best supportive care





Grade 1 Grade 2 Grade 3/4
Haematologic
Anaemia 13 8 5 0
Neutropenia 11 5 6 0
Lymphocytopenia 7 2 5 0
Thrombocytopenia 7 3 4 0
Nonhaematologic
Fatigue 32 23 9 0
Hypertension 21 18 3 0
Headache 21 17 4 0
Nausea and vomiting 13 6 7 0
Seizure 7 7 0 0
AST* increased 5 2 3 0
ALT† increased 4 1 3 0
Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase
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results of prospective trials on these regimens have been
published (Table 4), no standard treatment exists [9, 12,
16]. Thus, an individualized option that considers effi-
cacy, quality of life and toxicity is crucial.
The efficacy of systemic therapy in improving OS for
rHGG is unclear. Bevacizumab improved PFS with a me-
dian OS of 9 months in two randomized controlled trials
(RCTs) [9, 10]. Programmed death-1 (PD-1) immune
checkpoint inhibitor antibody showed a negative result
compared with bevacizumab, with a median OS of 9.8
months and median PFS of 1.5 months in the phase III
RCT Checkmate 143 trial [8].
HSRS and hypofractionated stereotactic radiotherapy
(HSRT) using linear accelerators take advantage of the
stereotactic precision as well as the properties of a
standard fractionation schedule. Irradiated recurrent tu-
mours allow a high treatment dose to cover the PTV
and minimize normal brain toxicity. In addition, the
condensed treatment schedule could be an important
option for rHGG patients with short expected survival
and poor KPS. HSRT has been reported to have a me-
dian overall survival for rHGG patients ranging from 12
to 12.7 months. Conti et al. reported a median survival
of 12 months for recurrent glioblastoma patients who
underwent HSRS reirradiation with temozolomide 75
mg/m2/day for 21 days every 28 days [17]. The prospect-
ive trial by Wuthrick reported a median survival of 12.7
months in grade 4 glioma patients using HSRT of 30 to
Fig. 2 a Survival time from salvage HSRS (OS-HSRS) of all rHGG patients; b OS-HSRS for WHO Grade 3 and 4 patients; c OS-HSRS for WHO Grade
4 patients who underwent concurrent bevacizumab with HSRS; d OS-HSRS for WHO Grade 4 patients who had KPS≤ 70 v > 70
Table 3 Multivariate Analysis of Survival after Salvage Treatment
in Grade 4 rHGG Patients
Factors Comparison HR 95%CI P
Age, years Continuous 1.03 0.98–1.08 0.250
KPS > 70 v ≤ 70 0.13 0.03–0.56 0.006
PTV, cm3 > 10 v ≤ 10 0.44 0.13–1.50 0.187
BED, Gy > 37.5 v ≤ 37.5 1.50 0.53–4.27 0.446
Concurrent† bevacizumab Yes v no 0.15 0.04–0.56 0.004
Abbreviations: HR hazard ratio, CI confidence interval, KPS Karnofsky
performance status, PTV planning target volume, BED biologically
effective dose
*BED was calculated using the LQ model with an alpha/beta ratio of 10
†Concurrent was defined as bevacizumab administered with HSRS
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42 Gy in 2.5 to 3.75 Gy fractions with 37.5 daily sunitinib
[15]. Fogh et al. reported the largest series retrospective
study of 147 patients using X-knife with a median dose
of 35 Gy in 10 fractions. The median survival achieved
11months [18]. Additionally, Shi et al. reported a cohort
of 36 grade 2 to 4 glioma patients using 30–35 Gy/10 fx
HSRT with alisertib who achieved a median overall sur-
vival of 11.1 months [19].
There are limited data addressing the combination of
systematic therapy and reirradiation for rHGG [20]. Sev-
eral prospective trials examined the safety and efficacy of
HSRT with systematic therapy for rHGG exhibiting OS
ranging from 12months to 12.7 months (Table 4). Min-
niti et al. examined HSRT with TMZ in 54 rHGG pa-
tients. With 30 Gy in 5 fractions plus concomitant TMZ
up to 12 cycles, the median survival after salvage treat-
ment was 12.4 months. KPS > 70 and grade 3 glioma
were considered prognostic factors for survival [16].
Effectiveness of CyberKnife re-irradiation for rHGG
CyberKnife is an image-guided stereotactic radiosurgery
system that can deliver accurate treatment doses to
brain lesions. In this study, we showed a median OS
after HSRS of 17.6 months (19.5 and 14.6 months for
grade 3 and 4 gliomas, respectively; p = 0.039). In the lit-
erature, the survival of grade 4 patients after CyberKnife
was reported to range from 10.6 to 13.7 months [21, 22].
The promising survival in this study is due to several
reasons. First, radiation was delivered with a relatively
low isodose line of 63 to 75% and resulted in a higher
dose delivered to the tumour. It increased the tumour
centre dose and enhanced the tumour cell killing activity
as a direct result as Romanelli et al. reported that the
normalized total dose can achieve 57 Gy (24 Gy in 3
fractions 80% isodose) for the tumour using an α/β = 10
linear quadratic model [23]. Second, all the enrolled pa-
tients received HSRS as first-line salvage treatment. For
these patients, survival was expected to be longer. Third,
24 (34.2%) patients underwent a second-course salvage
treatment after HSRS, including surgery, HSRS, systemic
therapy, and TTF.
Minimizing radiation injury to the normal brain was
considered when increasing the treatment dose. Bevaci-
zumab is an anti-vascular endothelial growth factor
(VEGF) monoclonal antibody that is used in recurrent
glioblastoma [9, 10]. Bevacizumab has been hypothesized
to protect the normal brain from radiation by reducing
brain oedema and radiation necrosis. The advantage of
adding bevacizumab to HSRS has not been fully illus-
trated. Philip el al theorized that the additional bevacizu-
mab sensitized the tumour endothelia to radiotherapy
and induced apoptosis [24]. Additionally, Kyle et al. con-
cluded that the perivascular niche and antitumour ef-
fects could be the reason.
Our data suggest that HSRS with concomitant bevaci-
zumab and good performance status result in improved
survival in grade 4 patients. These results are similar to
Sharma’s research that reported 53 GBM patients who
achieved a median survival of 11 months after gamma
knife radiosurgery, and radiosurgery was associated with
longer survival in good performance patients [25].
Additionally, Cuneo reported an OS of 11.2 months in
patients receiving bevacizumab and stereotactic radio-
surgery compared with 3.9 months for patients treated
with stereotactic radiosurgery alone [26]. However, the
preliminary results of RTOG1205 showed a negative result
of HSRT in improving OS [27]. A variety of radiotherapy
techniques used in the trial and a relatively larger median
PTV may contaminate the result. However, an improved
6-month PFS was achieved in the HSRT+BVZ group com-
pared with the BVZ only group, and a longer PFS can in-
crease the quality of life in brain tumour patients. For
rHGG patients who have few or other therapeutic options,
HSRS or HSRT combined with bevacizumab may repre-
sent a reasonable consideration.
Strengths and limitations
To date, this is the largest cohort of CyberKnife as a
first-line salvage treatment for recurrent high-grade gli-
oma within radiation field patients. Our study demon-
strates promising survival and mild toxicity using
CyberKnife radiosurgery for rHGG patients.
Table 4 Recent Prospective Trials of Recurrent High-grade Glioma
Treatment Author, Year Regimen Median Dose(Gy) Sample Size(N) MST (Months)
Systemic Therapy Reardon, 2017 [8] Nivolumab vs BVZ N/A Nivo = 184 BVZ = 185 9.8 vs 10.0
Wick, 2017 [9] Lomustine +BVZ vs Lomustine N/A L + BVZ = 228 L = 149 9.1 vs 8.6
Friedman, 2009 [10] BVZ vs BVZ + CPT11 N/A BVZ = 85 BVZ + CPT11 = 82 9.2 vs 8.7
TTF Stupp, 2012 [12] TTField vs Chemotherapy N/A TTF = 120 Chemotherapy = 117 6.6 vs 6
HSRT Clarke, 2017 [13] HSRT+BVZ 30 15 12.5
Miwa, 2014 [14] HSRT+TMZ 30 21 12.0
Wuthrick, 2014 [15] HSRT+Sunitinib 35 11 12.7(GBM)
Abbreviations: TTF Tumor Treatment Field, HSRT Hypofractionated stereotactic radiotherapy, BVZ Bevacizumab, TMZ Temozolomide, GBM Glioblastoma Multiforme
Guan et al. BMC Cancer          (2021) 21:123 Page 6 of 8
However, the retrospective nature limited this study.
Selection bias was created when deciding the eligible pa-
tients for salvage treatment, which increased the number
of potential good prognosis patients. Additionally, add-
itional systemic therapy, second-course salvage treat-
ment after HSRS and lack of imaging follow-up for
palliative care patients may influence the result. More-
over, both previous studies and clinical experience at
our centre [see Additional file 2] encountered the same
dilemma as irradiated brain tumours, and the diagnosis
of LR and RN was difficult [28, 29].
Despite the limitations, this study presented a promising
outcome of salvage HSRS. A prospective phase II study
HSCK-002 ClinicalTrials.gov identifier, NCT04197492, is
ongoing at our centre to further investigate the value of
HSRS and anlotinib (an oral novel multitarget tyrosine
kinase inhibitor targeting VEGF receptor, fibroblast
growth factor receptor and platelet-derived growth factor
receptor).
Conclusions
HSRS using the CyberKnife radiosurgery system showed
a favourable outcome and acceptable toxicity as a salvage
treatment for HGG at first recurrence. A prospective
phase II trial, HSCK-002 (ClinicalTrials.gov identifier:
NCT04197492), is ongoing to further evaluate the efficacy
of CyberKnife radiosurgery for rHGG.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12885-021-07856-y.
Additional file 1. Treatment of progression after CyberKnife
radiosurgery. This file gives the details of therapy to all the participants.
Additional file 2. The dilemma of the diagnosis of LR and RN. This pdf
shows two cases in our center indicating the difficulty in diagnosing the
local recurrence of HGG and radiation neurosis.
Abbreviations
rHGG: Recurrent high-grade gliomas; PFS: Progression-free survival;
GBM: Glioblastoma; PTV: Planning target volume; KPS: Karnofsky Performance
Status; OS: Overall survival; WHO: World Health Organization; GTV: Gross
tumor volume; CTV: Clinical tumor volume; BED: Biologically effective dose;
LR: Local recurrence; HSRS: Hypofractionated stereotactic radiosurgery;
RCT: Randomized control trials; PD-1: Programmed death-1;
HSRT: Hypofractionated stereotactic radiotherapy
Acknowledgements
This manuscript has not been published and is not under consideration for
publication elsewhere.
Authors’ contributions
Yun Guan, Ji Xiong, and Mingyuan Pan are co-first authors that contributed
equally to the work. Conception design and interpretation of data: Xin
Wang and Yun Guan. Statistical analysis: Yun Guan. Data acquisition: Li Pan,
Jiazhong Dai, Ji Xiong, Jing Li, Huaguang Zhu, Xiu Gong, Chao Li, Guan-
ghai Mei, and Xiaoxia Liu. Article revising: Wenyin Shi and Mingyuan Pan.
Enmin Wang and Xin Wang approved the final version to be published. The
authors read and approved the final manuscript.
Funding
The study was supported by research grant from the Science and
Technology Commission of Shanghai Municipality (No 16411954000).
Availability of data and materials
The datasets used and/or analyzed in this study are available from the
corresponding author on request.
Ethics approval and consent to participate
All procedures performed in this study were in accordance with the ethical
standards of the institutional and the 1964 Helsinki declaration and its later
amendments. This retrospective study was approved by the Huashan ethics
committee. All participants provided written informed consent and studies




All the authors have nothing to disclose.
Author details
1CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Fudan
University, 12 Wulumuqi Road (M), Shanghai 200040, China. 2Neurosurgical
Institute of Fudan University, 12 Wulumuqi Road (M), Shanghai 200040,
China. 3Shanghai Clinical Medical Center of Neurosurgery, 12 Wulumuqi
Road (M), Shanghai 200040, China. 4Shanghai Key Laboratory of Brain
Function and Restoration and Neural Regeneration, 12 Wulumuqi Road (M),
Shanghai 200040, China. 5Department of pathology, Huashan Hospital,
Fudan University, 12 Wulumuqi Road (M), Shanghai 200040, China.
6Department of Radiation Oncology, Thomas Jefferson University,
Philadelphia, PA, USA.
Received: 22 November 2020 Accepted: 11 January 2021
References
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin.
2006;56:106–30.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 2005;352:987–96.
3. Kirkpatrick JP, Sampson JH. Recurrent malignant gliomas. Semin Radiat
Oncol. 2014;24:289–98.
4. Martínez-Carrillo M, Tovar-Martín I, Zurita-Herrera M, et al. Salvage
radiosurgery for selected patients with recurrent malignant gliomas. Biomed
Res Int. 2014:657953.
5. Montemurro N, Perrini P, Blanco MO, et al. Second surgery for recurrent
glioblastoma: a concise overview of the current literature. Clin Neurol
Neurosurg. 2016;142:60–4.
6. Barbagallo GMV, Jenkinson MD, Brodbelt AR. Recurrent glioblastoma
multiforme, when should we reoperate? Br J Neurosurg. 2008;22:452–5.
7. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for
recurrent glioblastoma multiforme. J Clin Oncol. 2010;28:3838–43.
8. Reardon DA, Omuro A, Brandes AA, et al. OS10. 3 randomized phase 3
study evaluating the efficacy and safety of nivolumab vs bevacizumab in
patients with recurrent glioblastoma: CheckMate 143. Neuro-oncology.
2017;19(suppl_3):iii21.
9. Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in
progressive glioblastoma. N Engl J Med. 2017;377(20):1954–63.
10. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in
combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;
27(28):4733–40.
11. Wallner KE, Galicich JH, Krol G, et al. Patterns of failure following treatment
for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol
Biol Phys. 1989;16:1405–9.
12. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice
chemotherapy in recurrent glioblastoma: a randomised phase III trial of a
novel treatment modality. Eur J Cancer. 2012;48(14):2192–202.
13. Clarke J, Neil E, Terziev R, et al. Multicenter, phase 1, dose escalation study
of hypofractionated stereotactic radiation therapy with bevacizumab for
Guan et al. BMC Cancer          (2021) 21:123 Page 7 of 8
recurrent glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol
Phys. 2017;99(4):797–804.
14. Miwa K, Matsuo M, Ogawa S, et al. Re-irradiation of recurrent glioblastoma
multiforme using 11 C-methionine PET/CT/MRI image fusion for
hypofractionated stereotactic radiotherapy by intensity modulated radiation
therapy. Radiat Oncol. 2014;9(1):181.
15. Wuthrick EJ, Curran WJ Jr, Camphausen K, et al. A pilot study of
hypofractionated stereotactic radiation therapy and sunitinib in previously
irradiated patients with recurrent high-grade glioma. Int J Radiat Oncol Biol
Phys. 2014;90(2):369–75.
16. Minniti G, Scaringi C, De Sanctis V, et al. Hypofractionated stereotactic
radiotherapy and continuous low-dose temozolomide in patients with
recurrent or progressive malignant gliomas. J Neuro-Oncol. 2013;111(2):187–94.
17. Conti A, Pontoriero A, Arpa D, et al. Efficacy and toxicity of CyberKnife re-
irradiation and “dose dense” temozolomide for recurrent gliomas. Acta
Neurochir. 2012;154(2):203–9.
18. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation
therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol.
2010;28(18):3048.
19. Wenyin S, Erik S Blomain, Joshua Siglin, et al. Salvage fractionated
stereotactic re-irradiation (FSRT) for patients with recurrent high-grade
gliomas progressed after bevacizumab treatment. J Neuro-Oncol. 2018;
137(1):171–7.
20. Yazici G, Cengiz M, Ozyigit G, et al. Hypofractionated stereotactic
reirradiation for recurrent glioblastoma. J Neuro-Oncol. 2014;120(1):117–23.
21. Pinzi V, Orsi C, Marchetti M, et al. Radiosurgery reirradiation for high-grade
glioma recurrence: a retrospective analysis. Neurol Sci. 2015;36(8):1431–40.
22. Yersal Ö. Clinical outcome of patients with glioblastoma multiforme: single
center experience. J Oncol Sci. 2017;3(3):123–6.
23. Romanelli P, Conti A, Pontoriero A. Role of stereotactic radiosurgery and
fractionated stereotactic radiotherapy for the treatment of recurrent
glioblastoma multiforme. Neurosurg Focus. 2009;27(6):E8.
24. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab
with hypofractionated stereotactic irradiation for recurrent malignant
gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156–63.
25. Sharma M, Schroeder JL, Elson P, et al. Outcomes and prognostic
stratification of patients with recurrent glioblastoma treated with salvage
stereotactic radiosurgery. J Neurosurg. 2018;131(2):489–99.
26. Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and efficacy of
stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent
malignant gliomas. Int J Radiat Oncol Biol Phys. 2012;82(5):2018–24.
27. Tsien C, Pugh S, Dicker AP, et al. Randomized phase II trial of re-irradiation
and concurrent Bevacizumab versus Bevacizumab alone as treatment for
recurrent Glioblastoma (NRG oncology/RTOG 1205): initial outcomes and RT
plan quality report. Int J Radiat Oncol Biol Phys. 2019;105(1):S78.
28. Yomo S, Hayashi M. Salvage stereotactic radiosurgery with adjuvant use of
bevacizumab for heavily treated recurrent brain metastases: a preliminary
report. J Neuro-Oncol. 2016;127(1):119–26.
29. Guan Y, Wang C, Zhu H, et al. Hypofractionated radiosurgery plus
Bevacizumab for locally recurrent brain metastasis with previously high-
dose irradiation. World Neurosurg. 2020;133:e252–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Guan et al. BMC Cancer          (2021) 21:123 Page 8 of 8
